2022
DOI: 10.3390/medicina58081094
|View full text |Cite
|
Sign up to set email alerts
|

Chronic Thromboembolic Pulmonary Hypertension: An Observational Study

Abstract: Background and Objectives: Chronic thromboembolic pulmonary hypertension (CTEPH) has a high mortality. The treatment of CTEPH could be balloon pulmonary angioplasty (BPA), medical (MT) or pulmonary endarterectomy (PEA). This study aims to assess the clinical characteristics of CTEPH patients, surgically or medically treated, in a pulmonology referral center. Materials and Methods: A total of 124 patients with PH with suspected CTEPH (53 male subjects and 71 female subjects; mean age at diagnosis 67 ± 6) were a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
9
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 13 publications
(11 citation statements)
references
References 76 publications
0
9
0
Order By: Relevance
“…The most common cause of thromboembolism of the pulmonary artery and its branches in clinical practice is lower-limb venous thrombosis. 1,2 Acute right heart failure and/or circulatory shock caused by a dramatic increase in pulmonary vascular resistance are the main causes of death from APE, and drug treatment to alleviate neurohumoral factormediated pulmonary vasoconstriction might reduce APE-induced hemodynamic disturbances and improve prognosis. 3,4 Abnormal activation of the Rho/Rho kinase (ROCK) signaling pathway is involved in the formation of experimental pulmonary hypertension (PH), and ROCK inhibitors can prevent and reverse pulmonary vasoconstriction and pulmonary vascular remodeling during PH.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…The most common cause of thromboembolism of the pulmonary artery and its branches in clinical practice is lower-limb venous thrombosis. 1,2 Acute right heart failure and/or circulatory shock caused by a dramatic increase in pulmonary vascular resistance are the main causes of death from APE, and drug treatment to alleviate neurohumoral factormediated pulmonary vasoconstriction might reduce APE-induced hemodynamic disturbances and improve prognosis. 3,4 Abnormal activation of the Rho/Rho kinase (ROCK) signaling pathway is involved in the formation of experimental pulmonary hypertension (PH), and ROCK inhibitors can prevent and reverse pulmonary vasoconstriction and pulmonary vascular remodeling during PH.…”
Section: Introductionmentioning
confidence: 99%
“…The most common cause of thromboembolism of the pulmonary artery and its branches in clinical practice is lower-limb venous thrombosis. 1,2 Acute right heart failure and/or circulatory shock caused by a dramatic increase in pulmonary vascular resistance are the main causes of death from APE, and drug treatment to alleviate neurohumoral factor-mediated pulmonary vasoconstriction might reduce APE-induced hemodynamic disturbances and improve prognosis. 3,4…”
Section: Introductionmentioning
confidence: 99%
“…However, despite it being a promising treatment option for CTEPH, the available efficacy and safety data are based on single-arm, small-sample-size studies with large variations in patient characteristics (operable CTEPH and patients after PEA), disease characteristics, treatment approaches (BPA in addition to endarterectomy), and the duration of follow-up. The results should therefore be interpreted carefully, and further research is needed to establish the impact of BPA on survival, as well as in conjunction with medical therapy [ 17 , 18 , 19 ]. In this context, we aim to assess the efficacy and safety of the BPA procedure specifically in inoperable CTEPH patients without previous PEA or BPA in a low-volume single PH referral centre setting.…”
Section: Introductionmentioning
confidence: 99%
“…In addition to accurate preoperative/pre-interventional planning, CT diagnostics are also able provide evidence for the presence of pulmonary hypertension (PH) in patients with severe AS [ 3 , 4 , 5 ]. In the 2015 European Society for Cardiology (ESC) guidelines [ 6 ], a diameter of the main pulmonary artery (PA) ≥ 29 mm is considered potentially indicative of the presence of pulmonary hypertension, which is associated with a poor prognosis in terms of increased mortality in patients with severe AS.…”
Section: Introductionmentioning
confidence: 99%